|
|
|
The healthcare industry is rife with opportunity for biotechnology companies; antibodies and other proteins are increasingly
mainstream products in many clinical indications. The challenge for biotechnology companies is to develop sustainable business
models and create high value portfolios of innovative products. While historically out-licensing to big pharma was the only
option, today direct commercialization is not only feasible in some instances but the best route to building
shareholder value.
Health Advances has worked with over 100 companies, to explore strategic options for product development and for transitioning
from drug discovery or drug development organizations into more fully integrated companies.
- Start-up strategy
- Portfolio prioritization
- Product commercialization
- Clinical planning
- Partnership strategy
- Business strategy
|
|
 |
|
|
|
|
|
learn more
about our work in the biotechnology industry. |
|
|
|
|
 |
|
|